Ertugliflozin plus sitagliptin more effective than monotherapy with either | ADA

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • Ertugliflozin plus sitagliptin is more effective than either treatment alone for the reduction of HbA1c and fasting plasma glucose (FPG). 

Why this matters

  • Ertugliflozin is an oral sodium-glucose co-transporter 2 (SGLT2) inhibitor in development for the treatment of type...